Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FENTANYL TRANSDERMAL SYSTEM

All products: Limited Use (codes 689)

Sandoz Fentanyl Patch · PIN 09858348 · 12mcg/hr · Trans Patch

Limited Use — Reason for Use code 689 requiredOntario PIN; no Health Canada record under this code
StatusLimited Use — Reason for Use code 689 required
Write on scriptLU code 689 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 689
Reason for Use code 689 For the treatment of chronic pain in patients who have been stabilized on fentanyl and require the use of fentanyl 12mcg/hr patches for dose adjustment up or down to the lowest optimal opioid dose. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Sandoz Fentanyl Patch · DIN 09858348 Manufacturer: Sandoz Canada Inc.; listing date 2024-09-27 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check this DIN again

Sandoz Fentanyl Patch: Formulary list price $3.3200/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.3200 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858348)

Source record
DIN 09858348: Sandoz Fentanyl Patch Raw flags: sec12=Y, sec3=Y Item: 280808469; group id 403; item number 0962; lccId 00403; manufacturer id SDZ Source form: Trans Patch; strength: 12mcg/hr Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.3200; ministry $3.3200 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09858348 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Interchangeable products
Duragesic 12 · DIN 09858350 · not recorded Teva-Fentanyl · DIN 09858349 · $3.3200
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered

Matched class: 28:08:08 Opiate Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE, ACETAMINOPHEN & CODEINE PHOSPHATE, CODEINE PHOSPHATE, HYDROMORPHONE HCL, METHADONE HCL, MORPHINE SULFATE, OXYCODONE HCL & ACETAMINOPHEN, OXYCODONE HCL & ACETYLSALICYLIC ACID 28:08:08 Opiate Agonists

ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 300mg & 15mg & 15mg, 300mg & 15mg & 30mg · Tab

ACETAMINOPHEN & CODEINE PHOSPHATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 160mg & 8mg/5mL, 300mg & 30mg, 300mg & 60mg · O/L, Tab

CODEINE PHOSPHATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 15mg, 30mg · Tab

HYDROMORPHONE HCL

· 28 products · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) · strengths: 4.5mg, 9mg, 3mg, 6mg, 12mg, 18mg, 2mg/mL, 10mg/mL, 1mg/mL, 1mg, 2mg, 4mg, 8mg · CR Cap, Inj Sol-1mL Pk, Oral Sol, Tab

METHADONE HCL

· 16 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg/mL, 1mg, 5mg, 10mg, 25mg · Oral Concentrate, Oral Concentrate (Cherry Flavour), Oral Concentrate (Unflavoured), Tab

MORPHINE SULFATE

· 35 products · General benefit (31), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 10mg, 15mg, 30mg, 60mg, 100mg, 2mg/mL, 10mg/mL, 15mg/mL, 50mg/mL, 20mg, 50mg, 200mg, 5mg · ER Cap, Inj Sol Amp, Inj Sol-1mL Pk, SR Cap, SR Tab, Tab

OXYCODONE HCL & ACETAMINOPHEN

· 5 products · General benefit (4), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

OXYCODONE HCL & ACETYLSALICYLIC ACID

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

CODEINE SULFATE TRIHYDRATE & MONOHYDRATE

· 4 products · Limited Use, codes 201 · strengths: 50mg, 100mg, 150mg, 200mg · CR Tab

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg · Cap

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE & CODEINE PHOSPHATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg & 15mg, 330mg & 50mg & 40mg & 30mg · Cap

OXYCODONE HCL

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:08 and 2 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults: TEVA-FENTANYL (fentanyl transdermal system) is indicated for the management of pain severe enough to require daily, continuous, long-term opioid treatment and:  that is opioid-responsive;  and for which alternative options are inadequate Only for use in patients who are already receiving opioid therapy at a total daily dose of at least 60 mg/day Morphine Equivalents. TEVA-FENTANYL is not indicated as an as-needed (prn) analgesic. The initial dose of TEVA-FENTANYL should be obtained or calculated from the conversion tables (see DOSAGE AND ADMINISTRATION), and must not be higher than that dose which is equivalent to the total dose of opioids the patient is receiving at the time of the switch to the patch. Because serious or life-threatening hypoventilation could occur, TEVA-FENTANYL should not TEVA-FENTANYL (12, 25, 50, 75 and 100 mcg/h) Page 3 of 60 be used in:  non-opioid-tolerant patients  the management of post-operative pain Pediatrics (< 18 years of age): The safety and efficacy of fentanyl transdermal system has not been studied in the pediatric population. Therefore, the… https://pdf.hres.ca/dpd_pm/00066268.PDF PM date: June 10, 2022 Source product: TEVA-FENTANYL; DIN 02282941; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.